carocell bio

menu.png

Rapidly developing new, safer medicines.

 Carocell Bio (formerly Bridge Biotec) are developing new nanotechnology driven medicines to more safely & effectively treat serious inflammatory diseases. Our new peptide medicines switch off inflammation & prevent it's activation, thus opening the door to the $106 billion inflammatory market. We are seeking additional investment to prove that these compounds switch off inflammation in explanted human tissue. 
Find out how you can contribute to this exciting new medical breakthrough here.

Rapidly developing new, safer medicines.

 Carocell Bio (formerly Bridge Biotec) are developing new nanotechnology driven medicines to more safely & effectively treat serious inflammatory diseases. Our new peptide medicines switch off inflammation & prevent it's activation, thus opening the door to the $106 billion inflammatory market. We are seeking additional investment to prove that these compounds switch off inflammation in explanted human tissue. 
Find out how you can contribute to this exciting new medical breakthrough here.

new effective and safe treatment for inflammation

Treating inflammation & inflammatory diseases, more safely & effectively.

Carocell Bio is developing new peptide based nanotechnologies that will change the way we currently treat inflammation and related diseases.

Carocell Bio Limited (“Carocell”) is developing novel therapeutics to more safely & effectively treat life threatening and disabling inflammatory conditions such as inflammatory bowel disease (IBD), atopic dermatitis (AD, eczema), psoriasis and burns.

Inflammation refers to a biological response to stimuli, interpreted by the body to have a potentially harmful effect.  In certain situations, such as after injury, inflammation is a normal response. However, inflammatory diseases result in the immune system attacking the body’s own cells or tissues and may cause abnormal inflammation resulting in chronic pain, swelling, stiffness and damage to normal tissues.

Carocell’s novel medicines are short proteins (“peptides”) that are delivered into human cells using a patented, safe nano-polymer delivery technology. We have shown them to switch off inflammation in a recognised cellular model and also prevent the activation of inflammation. These short peptides that will be broken down into simple and naturally occurring amino acids, are highly active and exquisitely specific inflammation blockers, so only tiny doses will be required to cure serious inflammatory diseases.

Carocell is an ambitious company aiming to be revenue-generating within 3 years.

READ ABOUT OUR RESEARCH 

FIND OUT HOW YOU CAN INVEST IN OUR TECHNOLOGY

Dr Mike Davies at Biotech showcase 2019

This video is of Dr. Mike Davies discussing Carocell Bio's work with Christine Corrado of Proactive Investors.
As of august 14, 2019 Bridge Biotec became Carocell Bio Limited.

donate to assist our research

If you would like to make a donation to Carocell Bio to help us advance our research into inflammation treatments, please use the donate button below.

 donate-words-icon.png

talk to carocell bio about investing in our work

If you would like to speak to us in detail about investing, tax benefits, donating or assisting us in any way at all, please contact us via the details below and we will get back to you as soon as possible.

talk-to-carocell-icon.png

bridge biotec facebookbridge biotec twitterbridge biotec linkedinbridge-youtube-60x60.png

Contact

Email: contact@carocellbio.com
UK: +44 (0) 20 3097 1979
US: +1 212 863 9902

USA Office

Carocell Bio, Inc.
3411 Silverside Road,
Tatnall Building,
Suite 104,
Wilmington,
New Castle,
Delaware,
DE 19810
U.S.A.

UK Office

©2018 Carocell Bio Ltd.

The BioHub at Alderley Park
Mereside, Alderley Park
Macclesfield
SK10 4TG